JPS61176523A - 制癌剤 - Google Patents

制癌剤

Info

Publication number: JPS61176523A
Authority: JP; Japan
Prior art keywords: cancer; cells; differentiation; compound; strong
Prior art date: 1985-01-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP60016085A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0466453B2 (2

Inventor

Teruhiko Beppu

別府　輝彦

Yasushi Iwamoto

靖岩元

Minoru Yoshida

稔吉田

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-01-30

Filing date

1985-01-30

Publication date

1986-08-08

1985-01-30 Application filed by Individual filed Critical Individual

1985-01-30 Priority to JP60016085A priority Critical patent/JPS61176523A/ja

1986-01-24 Priority to US06/821,973 priority patent/US4690918A/en

1986-01-27 Priority to DE8686101047T priority patent/DE3682091D1/de

1986-01-27 Priority to EP86101047A priority patent/EP0196415B1/en

1986-08-08 Publication of JPS61176523A publication Critical patent/JPS61176523A/ja

1992-10-23 Publication of JPH0466453B2 publication Critical patent/JPH0466453B2/ja

Status Granted legal-status Critical Current

Links

230000003327 cancerostatic effect Effects 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 9
239000000203 mixture Substances 0.000 claims abstract description 7
239000002246 antineoplastic agent Substances 0.000 claims description 19
239000000126 substance Substances 0.000 claims description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 abstract description 32
201000011510 cancer Diseases 0.000 abstract description 30
230000004069 differentiation Effects 0.000 abstract description 18
208000032839 leukemia Diseases 0.000 abstract description 14
230000001939 inductive effect Effects 0.000 abstract description 13
231100000419 toxicity Toxicity 0.000 abstract description 10
230000001988 toxicity Effects 0.000 abstract description 10
230000000694 effects Effects 0.000 abstract description 9
241000700605 Viruses Species 0.000 abstract description 4
RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 abstract description 4
RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 abstract description 3
230000035755 proliferation Effects 0.000 abstract description 3
YECWTLGLNDDPGE-PIFXLSLCSA-N trichostatin C Chemical compound C(/[C@@H](C)C(=O)C=1C=CC(=CC=1)N(C)C)=C(/C)\C=C\C(=O)NO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YECWTLGLNDDPGE-PIFXLSLCSA-N 0.000 abstract description 3
YECWTLGLNDDPGE-UHFFFAOYSA-N trichostatin D Natural products C=1C=C(N(C)C)C=CC=1C(=O)C(C)C=C(C)C=CC(=O)NOC1OC(CO)C(O)C(O)C1O YECWTLGLNDDPGE-UHFFFAOYSA-N 0.000 abstract description 3
230000002401 inhibitory effect Effects 0.000 abstract description 2
239000003795 chemical substances by application Substances 0.000 abstract 2
230000001857 anti-mycotic effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 47
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
BNQSTAOJRULKNX-UHFFFAOYSA-N N-(6-acetamidohexyl)acetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
239000000243 solution Substances 0.000 description 7
239000003242 anti bacterial agent Substances 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
230000024245 cell differentiation Effects 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
102000001554 Hemoglobins Human genes 0.000 description 4
108010054147 Hemoglobins Proteins 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
230000001093 anti-cancer Effects 0.000 description 4
238000002651 drug therapy Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000011282 treatment Methods 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
241000714180 Rauscher mink cell focus-forming virus Species 0.000 description 2
208000021841 acute erythroid leukemia Diseases 0.000 description 2
-1 alkali metal salts Chemical class 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
231100000590 oncogenic Toxicity 0.000 description 2
230000002246 oncogenic effect Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
210000000468 rubriblast Anatomy 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000003760 tallow Substances 0.000 description 2
238000010998 test method Methods 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 1
244000039154 Erica Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
150000002169 ethanolamines Chemical class 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000009094 second-line therapy Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007447 staining method Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000009095 third-line therapy Methods 0.000 description 1
229930185603 trichostatin Natural products 0.000 description 1
239000012588 trypsin Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

JP60016085A 1985-01-30 1985-01-30 制癌剤 Granted JPS61176523A (ja)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
JP60016085A JPS61176523A (ja)	1985-01-30	1985-01-30	制癌剤
US06/821,973 US4690918A (en)	1985-01-30	1986-01-24	Use of trichostatin compounds for treating tumor cells
DE8686101047T DE3682091D1 (de)	1985-01-30	1986-01-27	Trichostatine a und c als antikrebsmittel.
EP86101047A EP0196415B1 (en)	1985-01-30	1986-01-27	Trichostatins a and c as antitumour drugs

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP60016085A JPS61176523A (ja)	1985-01-30	1985-01-30	制癌剤

Publications (2)

Publication Number	Publication Date
JPS61176523A true JPS61176523A (ja)	1986-08-08
JPH0466453B2 JPH0466453B2 (2)	1992-10-23

Family

ID=11906699

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP60016085A Granted JPS61176523A (ja)	1985-01-30	1985-01-30	制癌剤

Country Status (4)

Country	Link
US (1)	US4690918A (2)
EP (1)	EP0196415B1 (2)
JP (1)	JPS61176523A (2)
DE (1)	DE3682091D1 (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235688B1 (en)	2004-11-04	2007-06-26	University Of Notre Dame Du Lac	Process for preparing histone deacetylase inhibitors and intermediates thereof
JP2007262058A (ja) *	2006-03-03	2007-10-11	Tokyo Univ Of Science	糸状菌の分化抑制剤
JP2016528297A (ja) *	2013-08-22	2016-09-15	ヴァンダファーマシューティカルズインコーポレイテッド	癌治療

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0775593A (ja) *	1993-09-08	1995-03-20	Suntory Ltd	蛋白質の製造方法
EP0827946A1 (en) *	1996-09-04	1998-03-11	Vrije Universiteit Brussel	Inhibitors for the differentiation of cells, in particular hepatic stellate cells
CA2276306C (en) *	1996-12-30	2009-12-15	The Johns Hopkins University School Of Medicine	Loss of imprinting-based in vitro diagnostic method to determine the propensity to develop cancer
EP1332756A3 (en) *	1996-12-30	2003-12-10	The Johns Hopkins University School Of Medicine	Compositions and methods for restoring a normal pattern of imprinting to cells
US6387673B1 (en) *	1997-05-01	2002-05-14	The Salk Institute For Biological Studies	Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPO721997A0 (en) *	1997-06-06	1997-07-03	Queensland Institute Of Medical Research, The	Anticancer compounds
US6518012B1 (en)	1999-04-02	2003-02-11	Health Research, Inc.	Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation
US6544957B2 (en)	2000-01-04	2003-04-08	The Johns Hopkins University	Methods and reagents for facilitating transcription
WO2002055017A2 (en) *	2000-11-21	2002-07-18	Wake Forest University	Method of treating autoimmune diseases
AR035659A1 (es) *	2000-12-07	2004-06-23	Hoffmann La Roche	Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6613753B2 (en) *	2001-02-21	2003-09-02	Supergen, Inc.	Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
DE60113645T2 (de) *	2001-04-10	2006-07-06	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten
US6905669B2 (en) *	2001-04-24	2005-06-14	Supergen, Inc.	Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7241743B2 (en) *	2001-06-15	2007-07-10	The Trustees Of Columbia University In The City Of New York	Sir2α-based therapeutic and prophylactic methods
EP1443928B1 (en) *	2001-10-16	2011-07-27	Sloan-Kettering Institute For Cancer Research	Treatment of neurodegenerative diseases and cancer of the brain
US20030147813A1 (en) *	2002-02-07	2003-08-07	John Lyons	Method for treating chronic myelogenous leukemia
US6998391B2 (en) *	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
JP2005525345A (ja) *	2002-02-15	2005-08-25	スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ	Ｔｒｘ媒介性疾患を処置する方法
CA2503094A1 (en) *	2002-02-27	2003-09-04	The Ohio State University Research Foundation	Therapeutic methods for acute myeloid leukemia
US7148257B2 (en) *	2002-03-04	2006-12-12	Merck Hdac Research, Llc	Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20060276547A1 (en) *	2002-03-04	2006-12-07	Bacopoulos Nicholas G	Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) *	2002-03-04	2007-03-15	Bacopoulos Nicholas G	Methods of treating cancer with hdac inhibitors
US7456219B2 (en)	2002-03-04	2008-11-25	Merck Hdac Research, Llc	Polymorphs of suberoylanilide hydroxamic acid
WO2003075839A2 (en) *	2002-03-04	2003-09-18	Aton Pharma, Inc.	Methods of inducing terminal differentiation
US20040132825A1 (en) *	2002-03-04	2004-07-08	Bacopoulos Nicholas G.	Methods of treating cancer with HDAC inhibitors
CN100566711C (zh) *	2002-04-15	2009-12-09	斯隆-凯特林癌症研究院	治疗癌症的化合物及其用途
US6982253B2 (en) *	2002-06-05	2006-01-03	Supergen, Inc.	Liquid formulation of decitabine and use of the same
US20040162263A1 (en) *	2002-10-31	2004-08-19	Supergen, Inc., A Delaware Corporation	Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
DK2238982T3 (da)	2003-06-27	2013-01-28	Astellas Pharma Inc	Terapeutisk middel til blødt væv-sarcom
US20050037992A1 (en) *	2003-07-22	2005-02-17	John Lyons	Composition and method for treating neurological disorders
KR100924737B1 (ko) *	2003-08-26	2009-11-04	슬로안-케테링인스티튜트퍼캔서리서치	Ｈｄａｃ 억제제를 이용한 암의 치료 방법
US20050059682A1 (en) *	2003-09-12	2005-03-17	Supergen, Inc., A Delaware Corporation	Compositions and methods for treatment of cancer
WO2006007377A2 (en) *	2004-06-16	2006-01-19	The General Hospital Corporation	Methods of screening for bridge-1-mediated disorders, including type ii diabetes
US20060069060A1 (en) *	2004-09-27	2006-03-30	Sanjeev Redkar	Salts of decitabine
US20060063735A1 (en) *	2004-09-17	2006-03-23	Supergen, Inc.	Salts of 5-azacytidine
US20060128654A1 (en) *	2004-12-10	2006-06-15	Chunlin Tang	Pharmaceutical formulation of cytidine analogs and derivatives
US20060128653A1 (en) *	2004-12-10	2006-06-15	Chunlin Tang	Pharmaceutical formulation of decitabine
US7250416B2 (en) *	2005-03-11	2007-07-31	Supergen, Inc.	Azacytosine analogs and derivatives
TWI365068B (en) *	2005-05-20	2012-06-01	Merck Sharp & Dohme	Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20080292616A1 (en) *	2005-08-19	2008-11-27	Government Of The United Of America, Represented By The Secretary, Department Of Health And....	Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
US7700567B2 (en) *	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP2009514891A (ja) *	2005-11-04	2009-04-09	メルクエンドカムパニーインコーポレーテッド	癌を治療するためのｓａｈａ及びエルロチニブを用いる方法
US20070105792A1 (en) *	2005-11-04	2007-05-10	Dimartino Jorge F	Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
CA2636596A1 (en) *	2005-11-04	2007-05-18	James Pluda	Method of treating cancers with saha and pemetrexed
US20070117776A1 (en) *	2005-11-04	2007-05-24	John Lyons	Low Dose Therapy Of DNA Methylation Inhibitors
US20090018142A9 (en) *	2006-05-02	2009-01-15	Zhengping Zhuang	Use of phosphatases to treat tumors overexpressing N-CoR
US20100144885A1 (en) *	2006-09-29	2010-06-10	The Board Of Trustees Of The University Of Illinois	Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
CN101528037A (zh) *	2006-11-03	2009-09-09	默克公司	使用saha和硼替佐米治疗多发性骨髓瘤的方法
BRPI0806365B8 (pt)	2007-02-06	2021-05-25	Lixte Biotechnology Holdings Inc	composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
US8043804B2 (en) *	2007-05-23	2011-10-25	The Trustees Of Columbia University In The City Of New York	DBC1, a novel native inhibitor of anti-aging protein SIRT1
US20090035292A1 (en) *	2007-08-03	2009-02-05	Kovach John S	Use of phosphatases to treat neuroblastomas and medulloblastomas
JP5730575B2 (ja) *	2007-10-01	2015-06-10	リクスト・バイオテクノロジー，インコーポレイテッド	Ｈｄａｃ阻害剤
US8227473B2 (en) *	2008-08-01	2012-07-24	Lixte Biotechnology, Inc.	Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en)	2009-06-18	2010-12-23	Lixte Biotechnology, Inc.	Methods of modulating cell regulation by inhibiting p53
WO2010014141A1 (en) *	2008-08-01	2010-02-04	Lixte Biotechnology, Inc.	Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
WO2010014220A1 (en) *	2008-08-01	2010-02-04	Lixte Biotechnology, Inc.	Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
EP2750768B1 (en)	2011-08-30	2018-10-03	Astex Pharmaceuticals, Inc.	Decitabine derivative formulations
KR20160004299A (ko)	2013-04-09	2016-01-12	릭스트 바이오테크놀로지, 인코포레이티드	옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
BR112016003609B1 (pt) *	2013-08-22	2021-04-27	Vanda Pharmaceuticals Inc	Uso de tricostatina a em tratamento de mieloma múltiplo (mm)
US10669528B2 (en)	2015-06-25	2020-06-02	Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
AU2016287585B2 (en)	2015-07-02	2020-12-17	Otsuka Pharmaceutical Co., Ltd.	Lyophilized pharmaceutical compositions
WO2017161001A1 (en)	2016-03-15	2017-09-21	Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion
EP4324477A3 (en)	2016-12-08	2024-05-22	Lixte Biotechnology, Inc.	Oxabicycloheptanes for modulation of immune response
KR20200035438A (ko)	2017-08-03	2020-04-03	오쓰까 세이야꾸 가부시키가이샤	약물 화합물 및 이의 정제 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60149520A (ja) *	1984-01-13	1985-08-07	Ajinomoto Co Inc	抗腫瘍剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4218478A (en) *	1979-01-05	1980-08-19	Ruiko Oiwa	Trichostatin as an antiprotozoal agent

1985
- 1985-01-30 JP JP60016085A patent/JPS61176523A/ja active Granted
1986
- 1986-01-24 US US06/821,973 patent/US4690918A/en not_active Expired - Fee Related
- 1986-01-27 DE DE8686101047T patent/DE3682091D1/de not_active Expired - Lifetime
- 1986-01-27 EP EP86101047A patent/EP0196415B1/en not_active Expired - Lifetime

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60149520A (ja) *	1984-01-13	1985-08-07	Ajinomoto Co Inc	抗腫瘍剤

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235688B1 (en)	2004-11-04	2007-06-26	University Of Notre Dame Du Lac	Process for preparing histone deacetylase inhibitors and intermediates thereof
JP2007262058A (ja) *	2006-03-03	2007-10-11	Tokyo Univ Of Science	糸状菌の分化抑制剤
JP2016528297A (ja) *	2013-08-22	2016-09-15	ヴァンダファーマシューティカルズインコーポレイテッド	癌治療
US10265282B2 (en)	2013-08-22	2019-04-23	Vanda Pharmaceuticals Inc.	Cancer treatment
JP2019167351A (ja) *	2013-08-22	2019-10-03	ヴァンダファーマシューティカルズインコーポレイテッド	癌治療
JP2021105005A (ja) *	2013-08-22	2021-07-26	ヴァンダファーマシューティカルズインコーポレイテッド	癌治療
US11078289B2 (en)	2013-08-22	2021-08-03	Vanda Pharmaceuticals Inc.	Cancer treatment
US11667718B2 (en)	2013-08-22	2023-06-06	Vanda Pharmaceuticals Inc.	Cancer treatment
US12590162B2 (en)	2013-08-22	2026-03-31	Vanda Pharmaceuticals Inc.	Cancer treatment

Also Published As

Publication number	Publication date
US4690918A (en)	1987-09-01
EP0196415A2 (en)	1986-10-08
EP0196415B1 (en)	1991-10-23
JPH0466453B2 (2)	1992-10-23
EP0196415A3 (en)	1988-09-07
DE3682091D1 (de)	1991-11-28

Publication	Publication Date	Title
JPS61176523A (ja)	1986-08-08	制癌剤
US5244922A (en)	1993-09-14	Methods for treating viral infections
US5672603A (en)	1997-09-30	Apoptosis regulating composition
ES2312884T3 (es)	2009-03-01	Composiciones antivirales que comprenden derivados de acido fenilacetico.
EP1369119B1 (en)	2008-12-17	Il-12 expression controlling agents
KR20190009790A (ko)	2019-01-29	Apds의 치료에 사용하기 위한 특정 트리플루오로에틸 퀴놀린 유사체
WO2022237293A1 (zh)	2022-11-17	烟酰胺单核苷酸及其在抗肿瘤药物心肌损伤中的保护应用
Li et al.	2022	Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response
WO2021180093A1 (zh)	2021-09-16	吡咯并嘧啶化合物的治疗噬血细胞综合征的用途
Poydock et al.	1979	Inhibiting effect of vitamins C and B12 on the mitotic activity of ascites tumors
CN116236482A (zh)	2023-06-09	莲心碱在治疗nlrp3炎症小体异常活化相关疾病中的应用
US20200230115A1 (en)	2020-07-23	Methods of treating influenza-associated viral pneumonia
CN115227687A (zh)	2022-10-25	浅蓝菌素在制备防治nlrp3炎症小体相关疾病的药物中的应用
US5089508A (en)	1992-02-18	Methods for treating aids
JP5145563B2 (ja)	2013-02-20	神経変性疾患治療薬
Sodhi et al.	1992	Production of reactive nitrogen intermediates by bone marrow‐derived macrophages on treatment with cisplatin in vitro
Chen et al.	2024	Interference with histone deacetylase 4 regulates C-jun N-terminal kinase/activating protein-1 signaling to ameliorate sepsis-induced alveolar epithelial cell injury
CA2300792A1 (en)	2000-09-19	An agent for increasing chemokine production
RU2814013C1 (ru)	2024-02-21	Способ использования 4-((5,10-диметил-6-оксо-6,10-дигидро-5Н-пиримидо[5,4-b]тиено[3,2-e][1,4]диазепин-2-ил)амино)бензолсульфонамида (XMU-MP-1) для подавления роста клеток лимфомы Беркитта
Dore-Duffy et al.	1984	Oral administration of prostaglandin E2 to humans: Effects on peripheral blood leukocyte function
RU2784809C2 (ru)	2022-11-29	Комбинированный продукт, содержащий дициклоплатин, и способ его получения и применения
US5658912A (en)	1997-08-19	Apoptosis regulating composition
Birch	1999	Biomedical uses of lithium
CN118236361A (zh)	2024-06-25	牛磺酸联合化疗药物在制备抗肿瘤药物中的应用
CN121445746A (zh)	2026-02-03	Um729在制备预防和/或治疗心肌细胞缺氧损伤药物中的应用